Health Canada approves Ibsrela to treat irritable bowel syndrome with constipation.- Knight Therapeutics

Knight Therapeutics Inc., has announced that Health Canada has approved Ibsrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight and Ardelyx, Inc. signed an agreement in March 2018 granting Knight the exclusive right to distribute Ibsrela in Canada for IBS-C and hyperphosphatemia. Ibsrela is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients. On September 12, 2019, the FDA approved Ibsrela for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.